In 1928, Alexander Fleming noticed that a mold had contaminated one of his petri dishes and killed the bacteria around it. He called the substance penicillin. Within two decades, antibiotics had transformed medicine so fundamentally that operations, organ transplants, cancer chemotherapy, and routine surgery — all of which depend on the ability to prevent and treat bacterial infection — became possible.
The era those antibiotics made possible may be ending.
A 2024 study published in The Lancet estimated that antimicrobial resistance — the growing ability of bacteria, viruses, fungi, and parasites to defeat the drugs designed to kill them — directly caused 1.27 million deaths in 2019 and contributed to nearly 5 million more. By 2050, on current trajectories, antimicrobial resistance is projected to kill 10 million people per year — more than cancer currently kills.
The metaphor that public health officials use most often is the return of the pre-antibiotic era. Strep throat, pneumonia, urinary tract infections, infected wounds — conditions that are now routine and manageable — would once again become life-threatening. Surgery would carry risks comparable to those of the 19th century. The entire structure of modern medicine, which presupposes the ability to control bacterial infection, would require fundamental revision.
This is not science fiction. It is the direction current data points, and it is arriving faster than most public awareness reflects.
How Resistance Works — and Why It Is Inevitable
Antibiotic resistance is, at its most basic level, evolution. When a population of bacteria is exposed to an antibiotic, the vast majority die. A small number with natural genetic mutations that happen to confer resistance survive. They reproduce. Their offspring are resistant. The antibiotic is now less effective against this population.
This process is not a flaw in how antibiotics work. It is a law of natural selection. It cannot be prevented — only slowed. The question is never whether resistance will develop to a given antibiotic, but how quickly.
Several human behaviors have dramatically accelerated the natural rate of resistance development. The most significant is overuse and misuse of antibiotics.
Globally, antibiotics are extensively prescribed for viral infections — colds, flu, most sore throats — against which they are entirely ineffective. The antibiotic does nothing to treat the virus, but it kills susceptible bacteria in the patient’s gut and body, creating selection pressure that favors resistant strains. In many low- and middle-income countries, antibiotics are sold without prescription, self-prescribed in incorrect doses for incorrect durations, and used as a first response to any illness. Globally, antibiotic use increased by 65% between 2000 and 2015.
Agriculture is the larger problem. In the United States, approximately 70-80% of all antibiotics sold by weight are given to livestock and poultry — not to treat disease, but to promote growth and prevent infection in crowded industrial farming conditions. The bacteria in farm animals develop resistance. Those bacteria enter the food chain, the soil, and the water table. Resistant strains that evolve in agricultural settings are regularly detected in human infections.
Hospitals are both the front line of treatment and a primary site of resistance generation. Patients with weakened immune systems, invasive devices, and severe infections receive high doses of broad-spectrum antibiotics — creating intense selection pressure in precisely the environments where the most vulnerable people are present.
The Pipeline Problem
When resistance to existing antibiotics was first identified as a significant concern in the 1990s, the standard response was: the pharmaceutical industry will develop new antibiotics. The problem is that it largely has not.
The economic logic of antibiotic development is deeply unfavorable. Developing a new antibiotic costs approximately $1-1.5 billion and takes 10-15 years. Once approved, the ideal public health use of a new antibiotic is to keep it in reserve — to use it only in cases of last resort, when other options have failed. This minimizes the development of resistance. It also means that a company that has spent $1 billion developing a drug sells very few units of it.
Compare this to a daily pill for a chronic condition — blood pressure medication, statins, antidepressants — which is prescribed to millions of patients indefinitely. The return on investment is simply not comparable. Most major pharmaceutical companies exited antibiotic development between the 1990s and 2010s. The small number of companies still in the space are primarily funded by public grants and government incentive programs, not by commercial prospects.
The pipeline of new antibiotics in development is the thinnest it has been in decades. The antibiotics in late-stage clinical trials are mostly incremental improvements on existing classes — useful, but insufficient against the most resistant strains, which have evolved mechanisms that defeat entire classes of drugs simultaneously.
The Superbugs Already Here
The clinical reality of antimicrobial resistance is not hypothetical. It is present in hospitals in every country.
MRSA (methicillin-resistant Staphylococcus aureus) became infamous in the 2000s as a hospital-acquired infection that killed patients with intact immune systems. It remains a serious and widespread threat. But MRSA is now almost a historical benchmark — the superbug of a previous era.
Carbapenem-resistant Enterobacteriaceae (CRE) — bacteria resistant to carbapenems, which are the antibiotics of last resort for many Gram-negative infections — have spread globally. Infections with some CRE strains carry mortality rates of 40-50%, even with optimal treatment, because “optimal treatment” may mean there is no effective drug available and clinicians are using drugs that partially work or that have significant toxicity.
NDM-1 (New Delhi Metallo-beta-lactamase), an enzyme that confers resistance to nearly all antibiotics, was first identified in 2009 and is now found on every continent. ESBL-producing bacteria — strains that break down the beta-lactam ring central to penicillin-type antibiotics — are increasingly common causes of urinary tract infections, wound infections, and pneumonia in community settings.
Pan-resistant Acinetobacter baumannii — resistant to every known antibiotic — has been detected in multiple countries. Infections with truly pan-resistant organisms leave clinicians with nothing. The patient either survives on the strength of their immune system or does not survive.
What Would Actually Help
The response to antimicrobial resistance requires action across multiple dimensions simultaneously.
Stewardship: Reducing unnecessary antibiotic use in humans and animals is the highest-leverage immediate intervention. Every unnecessary antibiotic prescription accelerates resistance development. Hospital antibiotic stewardship programs, which require physician justification for antibiotic prescriptions and restrict the use of broad-spectrum antibiotics to confirmed resistant infections, demonstrably slow resistance development in the hospitals that implement them.
Agricultural reform: Removing antibiotics used for growth promotion from agricultural use — as has already been done in the European Union — reduces the primary source of selection pressure globally. This requires regulation, monitoring, and the development of alternative approaches to preventing infection in industrial animal agriculture.
Economic incentives: The market failure in antibiotic development requires correction through policy. Several models have been proposed, including “pull incentives” — guaranteed payments to companies that successfully bring new antibiotics to market, paid regardless of sales volume. This separates the return on investment from the unit sales volume, allowing antibiotics to be held in reserve without destroying the economic case for developing them.
Diagnostics: Rapid point-of-care diagnostics that identify the specific pathogen causing an infection — and its resistance profile — within minutes rather than days would allow targeted antibiotic use rather than empirical broad-spectrum treatment. Reducing the diagnostic lag is one of the most important underinvested interventions in antimicrobial resistance strategy.
International coordination: Resistance genes move across borders in people, animals, food, and water. No country’s stewardship program can succeed if resistant strains are continuously reintroduced from countries with weaker programs. The WHO Global Action Plan on Antimicrobial Resistance, adopted in 2015, established a framework — but implementation remains deeply uneven.
The Stakes
The antimicrobial resistance crisis does not generate the visual drama of a pandemic or the political electricity of a natural disaster. People dying of untreatable infections look, individually, like people dying of infections. The resistance dimension is invisible to the patient in the bed.
This invisibility may be the single biggest obstacle to adequate response. The global mobilization of resources, political will, and public attention that occurred around COVID-19 has not occurred around antimicrobial resistance, despite the fact that the projected mortality from AMR dwarfs the COVID-19 death toll even in pessimistic pandemic scenarios.
The post-antibiotic future is not one in which modern medicine disappears. It is one in which modern medicine becomes considerably more dangerous, expensive, and uncertain. Cancer chemotherapy — which requires antimicrobial protection — becomes higher risk. Hip replacements become higher risk. Organ transplants become higher risk. Childbirth becomes higher risk.
We are not there yet. We have the window to act. But that window is measured in years, not decades, and it is closing at the pace of bacterial evolution.
Also explore:
The Biggest Global Risks of the Next Decade
AI in Healthcare: Revolution, Risk, and the Patient Privacy Dilemma (coming August 13)
The Next 30 Years: What the World Will Look Like
Sources & Further Reading
- WHO — Fact Sheets — concise evidence summaries by health topic.
- Our World in Data — Mental Health — prevalence data across countries and time.
- World Health Organization — Mental Health — global evidence and definitions on mental health.
- Our World in Data — Fertility Rate — the long-run demographic record behind birth-rate claims.
Related Articles
- Vaccine Mandates: Balancing Public Health and Personal Freedom
- Human Augmentation Ethics: The Slippery Slope to Redefining Humanity
- Designer Baby Ethics Debate: Playing God or Healthier Humanity?
Weekly Geopolitical Briefing
Go Beyond the Headlines
Analysis of the forces shaping the world - delivered every week. No noise, no bias, just depth.
Subscribe Free ?No spam. Unsubscribe anytime.
About the Author
António Monteiro
Engineer by profession, geopolitical analyst by conviction. I believe responsibility for the planet's future doesn't belong only to governments and institutions - it belongs to all of us. Knowledge about geopolitics, international conflicts, and the forces shaping the world is the most powerful tool for becoming more conscious, informed citizens. You don't need to be a diplomat to understand what's at stake - you just need to want to go beyond the headlines. At Outside The Case, I analyze conflicts, power dynamics, and global trends with rigor and accessible language, so you can understand what's really happening in the world.
Read more about the author →